BOLERO-@ , a phase III randomized trial , compared EVE ( @mg/d ) and placebo ( PBO ) , both plus EXE ( @ mg/d ) , in @ postmenopausal women with HR ( + ) advanced breast cancer recurring/progressing after treatment with NSAIs .